A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)

ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).

Study Overview

• Status: Active, not recruiting
• Conditions: Primary Hyperoxaluria Type 1; Primary Hyperoxaluria
• Intervention / Treatment: Drug: Lumasiran

• Study Type: Interventional
• Enrollment (Actual): 21
• Phase: Phase 3

Expanded Access

Approved for sale to the public. See expanded access record.

Contacts and Locations

Study Locations

• Australia
  • Garran, Australia
    • Clinical Trial Site
• Belgium
  • Brussels, Belgium
    • Clinical Trial Site
• France
  • Bron, France
    • Clinical Trial Site
  • Lyon, France
    • Clinical Trial Site
• Israel
  • Haifa, Israel
    • Clinical Trial Site
  • Nahariya, Israel
    • Clinical Trial Site
• Italy
  • Rome, Italy
    • Clinical Trial Site
• Jordan
  • Irbid, Jordan
    • Clinical Trial Site
• Lebanon
  • Beirut, Lebanon
    • Clinical Trial Site
• Netherlands
  • Amsterdam, Netherlands
    • Clinical Trial Site
• Turkey
  • Yenimahalle, Turkey
    • Clinical Trial Site
• United Arab Emirates
  • Dubai, United Arab Emirates
    • Clinical Trial Site
• United States
  • Minnesota
    • Rochester, Minnesota, United States, 55902
      • Clinical Trial Site
  • Texas
    • Houston, Texas, United States, 77030
      • Clinical Trial Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Has documented diagnosis of primary hyperoxaluria type 1 (PH1)
• Estimated glomerular filtration rate (eGFR) ≤45 mL/min/1.73 m^2 for patients ≥12 months of age (<12 months of age, must have serum creatinine considered elevated for age)
• Meets plasma oxalate level requirements
• If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days
• If on dialysis, may be on hemodialysis therapy only and must have been on a stable regimen for at least 4 weeks

Exclusion Criteria:

• Hemodialysis/peritoneal dialysis combination therapy or peritoneal dialysis alone
• Diagnosis of conditions other than PH1 contributing to renal insufficiency
• History of liver transplant
• History of kidney transplant and currently receiving immunosuppressants

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lumasiran; All patients will receive open-label lumasiran.	Drug: Lumasiran; Lumasiran will be administered by subcutaneous (SC) injection.; Other Names: ALN-GO1; OXLUMO

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cohort A: Percent Change in Plasma Oxalate From Baseline to Month 6	Percent change in plasma oxalate (umol/L) was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. For Cohort A, the baseline was defined as the mean of all plasma oxalate level values collected prior to the first dose of lumasiran.	Baseline to Month 6
Cohort B: Percent Change in Pre-dialysis Plasma Oxalate From Baseline to Month 6	Percent change in plasma oxalate (umol/L) was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. For Cohort B, the baseline is defined as the mean of the last four pre-dialysis plasma oxalate samples collected prior to the first dose of lumasiran. In Cohort B, only pre-dialysis samples are utilized.	Baseline to Month 6

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cohort B: Percent Change in Plasma Oxalate Area Under the Curve From 0-24 Hours [AUC(0-24)] Between Dialysis Sessions From Baseline to Month 6	Percent change in plasma oxalate AUC(0-24) was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. Baseline was defined as the mean value of all valid AUC (μmol/L/24h) profiles being computed prior to the first dose of lumasiran.	Baseline to Month 6
Absolute Change in Plasma Oxalate From Baseline to Month 6	Absolute change in plasma oxalate was estimated by an average absolute change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. For Cohort A, the baseline was defined as the mean of all plasma oxalate level values collected prior to the first dose of lumasiran; for Cohort B, the baseline was defined as the mean of the last 4 pre-dialysis plasma oxalate level values collected prior to the first dose of lumasiran. In Cohort B patients, the plasma oxalate baseline was similarly defined except that the values obtained from the plasma oxalate profile assessment visits only included the pre-dialysis sample collected per visit.	Baseline to Month 6
Cohort A: Absolute Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6	Absolute change in 24-hour urinary oxalate excretion corrected for BSA was estimated by an average absolute change from baseline across Months 3 through 6. Only valid urine samples without any non-protocol-related issues were included in the analysis. A negative change from Baseline indicates a favorable outcome. Baseline is defined as the median of all valid 24-hr urine assessments collected prior to the first dose date/time of lumasiran without any non-protocol-related sample issues.	Baseline to Month 6
Cohort A: Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6	Percent change in 24-hour urinary oxalate excretion corrected for BSA was estimated by an average percent change from baseline across Months 3 through 6. Only valid urine samples without any non-protocol-related issues were included in the analysis. A negative change from Baseline indicates a favorable outcome. Baseline is defined as the mean of all assessments prior to the first dose date/time of lumasiran.	Baseline to Month 6
Cohort A: Absolute Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6	Absolute change in spot urinary oxalate:creatinine ratio was estimated by an average absolute change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. Baseline was defined as the mean of all assessments prior to the first dose date/time of lumasiran.	Baseline to Month 6
Cohort A: Percent Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6	Percent change in spot urinary oxalate:creatinine ratio was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome. Baseline was defined as the mean of all assessments prior to the first dose date/time of lumasiran.	Baseline to Month 6
Change in Quality of Life As Assessed by Pediatric Quality of Life Inventory (PedsQL) Total Score From Baseline to Month 6 in Patients >=2 to 18 Years of Age at Time of Informed Consent	Peds-QL is a modular approach to measuring quality of life (QOL) in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Generic Core Scales contain 23 items designed to measure core domains of health (physical, emotional, and social functioning) and role (school functioning). Scores are summarized as Total Scale Score, Physical Health Summary Score, and Psychosocial Health Summary Score. The Total Scale Score will be reported for this study. The PedsQL will be completed by patients (or caregivers, as appropriate) who are ≥2 to <18 years of age at the time of consent. Total score range: 0 - 100, with higher scores indicating better health-related quality of life (HRQoL). Baseline is defined as last non-missing value collected prior to the first dose of lumasiran.	Baseline to Month 6
Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients ≥18 Years of Age at Time of Informed Consent	The KDQOL questionnaire is used to assess 3 core domains of kidney disease including: burden, symptoms/problems, and effects of kidney disease on daily life. The KDQOL subscales (Burden of Kidney Disease, Effect of Kidney Disease on Daily Life, and Symptoms and Problems of Kidney Disease), and the accompanying Short Form-12 (SF-12) Physical Component Summary and Mental Component Summary will be assessed for this study. These will be completed by patients who are ≥18 years of age at the time of consent. Score range (per domain): 0 - 100; higher scores indicate better HRQoL. Baseline is defined as last non-missing value collected prior to the first dose of lumasiran.	Baseline to Month 6
Maximum Plasma Concentration (Cmax) of Lumasiran	Cmax is the highest concentration of lumasiran in the plasma after a dose is given.	Day 1; Month 6
Time to Maximum Plasma Concentration (Tmax) of Lumasiran	Tmax is the time it takes for lumasiran to reach the maximum concentration (Cmax) after administration.	Day 1; Month 6
Elimination Half-life (t½β) of Lumasiran	t½β is the time it takes for the concentration of the drug in the plasma to be reduced by 50%.	Day 1; Month 6
Area Under the Concentration-time Curve From 0 to 24 Hours [AUC(0-24)] for Lumasiran	AUC(0-24) is the area under the plasma concentration-time curve over the last 24-h dosing interval.	Day 1; Month 6
Apparent Clearance (CL/F) of Lumasiran	CL/F is the rate at which lumasiran is eliminated from the body.	Day 1; Month 6
Apparent Volume of Distribution (V/F) of Lumasiran	V/F is the propensity of lumasiran to either remain in the plasma or redistribute to other tissues.	Day 1; Month 6
Percent Change in Plasma Oxalate Area Under the Curve From 0-24 Hours [AUC(0-24)] Between Dialysis Sessions From Baseline to Month 60		Baseline to Month 60
Absolute Change in Plasma Oxalate From Baseline to Month 60		Baseline to Month 60
Absolute Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 60		Baseline to Month 60
Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 60		Baseline to Month 60
Absolute Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 60		Baseline to Month 60
Percent Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 60		Baseline to Month 60
Change in Quality of Life As Assessed by Pediatric Quality of Life Inventory (PedsQL) Total Score From Baseline to Month 60 in Patients >=2 to 18 Years of Age at Time of Informed Consent	Peds-QL is a modular approach to measuring quality of life (QOL) in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Generic Core Scales contain 23 items designed to measure core domains of health (physical, emotional, and social functioning) and role (school functioning). Scores are summarized as Total Scale Score, Physical Health Summary Score, and Psychosocial Health Summary Score. The Total Scale Score will be reported for this study. The PedsQL will be completed by patients (or caregivers, as appropriate) who are ≥2 to <18 years of age at the time of consent. Total score range: 0 - 100, with higher scores indicating better health-related quality of life (HRQoL). Baseline is defined as last non-missing value collected prior to the first dose of lumasiran.	Baseline to Month 60
Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 60 in Patients ≥18 Years of Age at Time of Informed Consent	The KDQOL questionnaire is used to assess 3 core domains of kidney disease including: burden, symptoms/problems, and effects of kidney disease on daily life. The KDQOL subscales (Burden of Kidney Disease, Effect of Kidney Disease on Daily Life, and Symptoms and Problems of Kidney Disease), and the accompanying Short Form-12 (SF-12) Physical Component Summary and Mental Component Summary will be assessed for this study. These will be completed by patients who are ≥18 years of age at the time of consent. Score range (per domain): 0 - 100; higher scores indicate better HRQoL. Baseline is defined as last non-missing value collected prior to the first dose of lumasiran.	Baseline to Month 60
Percent Change in Plasma Oxalate From Baseline to End of Study		Baseline to Month 60
Change in Nephrocalcinosis From Baseline to End of Study	Nephrocalcinosis will be assessed by renal ultrasound.	Baseline to Month 60
Change in Frequency of Dialysis From Baseline to End of Study		Baseline to Month 60
Change in Mode of Dialysis From Baseline to End of Study	Modes of dialysis are defined as hemodialysis and peritoneal dialysis.	Baseline to Month 60
Change in Frequency of Renal Stone Events From Baseline to End of Study		Baseline to Month 60
Change in Renal Function Assessed by Estimated Glomerular Filtration Rate (eGFR) From Baseline to End of Study		Baseline to Month 60
Change in Measures of Systemic Oxalosis From Baseline to End of Study	Systemic oxalosis will be assessed in cardiac, skeletal, ophthalmologic, and dermatologic systems.	Baseline to Month 60

Collaborators and Investigators

• Sponsor: Alnylam Pharmaceuticals
• Investigators: Study Director: Medical Director, Alnylam Pharmaceuticals

Publications and helpful links

General Publications

• Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. Am J Kidney Dis. 2023 Feb;81(2):145-155.e1. doi: 10.1053/j.ajkd.2022.05.012. Epub 2022 Jul 14.

Study record dates

Study Major Dates

• Study Start (Actual): January 21, 2020
• Primary Completion (Actual): May 18, 2021
• Study Completion (Estimated): July 1, 2025

Study Registration Dates

• First Submitted: October 31, 2019
• First Submitted That Met QC Criteria: November 4, 2019
• First Posted (Actual): November 5, 2019

Study Record Updates

• Last Update Posted (Actual): April 22, 2024
• Last Update Submitted That Met QC Criteria: April 17, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: siRNA; PH1; Primary Hyperoxaluria; Hyperoxaluria; AGT; RNAi Therapeutic; Systemic Oxalosis
• Additional Relevant MeSH Terms: Metabolic Diseases; Kidney Diseases; Urologic Diseases; Genetic Diseases, Inborn; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Hyperoxaluria; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Hyperoxaluria, Primary; Renal Agents; Lumasiran
• Other Study ID Numbers: ALN-GO1-005; 2019-001346-17 (EudraCT Number); 2023-503382-29-00 (Ctis)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.

Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Requests for access to data can be submitted via the website www.vivli.org.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No